|Efalizumab (Code C68831)|
|Terms & Properties|
Preferred Name: Efalizumab
Definition: A humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. Efalizumab binds to CD11a, which is expressed on all leukocytes, resulting in a reduction in the cell surface expression of CD11a. In addition, this agent inhibits the binding of LFA-1 to intercellular adhesion molecule-1 (ICAM-1), resulting in the inhibition of leukocyte adherence and the suppression of cell-mediated immunity. LFA-1 binding to ICAM-1 is involved in the activation of T lymphocytes, adhesion of T lymphocytes to endothelial cells, and migration of T lymphocytes to sites of inflammation.
NCI-GLOSS Definition: A monoclonal antibody used to treat psoriasis (a chronic skin disease). It is also being studied in the treatment of graft-versus-host disease (GVHD) of the skin after a donor stem cell transplant. Efalizumab binds to a molecule called LFA-1, and blocks the action of T cells (a type of white blood cell). It is a type of immunosuppressant.
NCI Metathesaurus Link: C1320125 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||214745-43-4 (see NLM ChemIDplus info)|
|FDA UNII Code||XX2MN88N5D|
|PDQ Closed Trial Search ID||553413|
|PDQ Open Trial Search ID||553413 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|